Arthur Sands, Nurix Therapeutics CEO

Seagen teams up with pro­tein degra­da­tion spe­cial­ist to make a new kind of an­ti­body con­ju­gate, pay­ing $60M up­front

Seagen, whose suite of an­ti­body-drug con­ju­gates en­ticed Pfiz­er to a $43 bil­lion buy­out, is look­ing to put a twist on the idea.

The Seat­tle-based drug­mak­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.